David M Page, MD | |
520 Mary St, Ste 340, Evansville, IN 47710-1677 | |
(812) 450-6700 | |
(812) 450-6710 |
Full Name | David M Page |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 24 Years |
Location | 520 Mary St, Evansville, Indiana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1598768848 | NPI | - | NPPES |
000000305215 | Other | IN | BCBS PIN |
200292540 | Medicaid | IN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 01055360A (Indiana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Deaconess Hospital Inc | Evansville, IN | Hospital |
Methodist Hospital | Henderson, KY | Hospital |
Hamilton Pointe Health And Rehab | Newburgh, IN | Nursing home |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Deaconess Clinic Inc | 3375610116 | 337 |
News Archive
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.
BioRelix, Inc. today announced that it has entered into a research collaboration agreement with a subsidiary of Merck & Co., Inc. to identify new antibacterial drug candidates.
Marking another significant milestone for GE Healthcare's information technology business, the Ohio Pharmacy Board has approved the company's advanced ePrescribing solution for use by the state's physicians. Ohio is the only state today requiring two-factor authentication.
› Verified 2 days ago
Entity Name | Deaconess Clinic Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1619123585 PECOS PAC ID: 3375610116 Enrollment ID: O20080922000145 |
News Archive
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.
BioRelix, Inc. today announced that it has entered into a research collaboration agreement with a subsidiary of Merck & Co., Inc. to identify new antibacterial drug candidates.
Marking another significant milestone for GE Healthcare's information technology business, the Ohio Pharmacy Board has approved the company's advanced ePrescribing solution for use by the state's physicians. Ohio is the only state today requiring two-factor authentication.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
David M Page, MD Po Box 1510, Evansville, IN 47706-1510 Ph: (812) 450-6700 | David M Page, MD 520 Mary St, Ste 340, Evansville, IN 47710-1677 Ph: (812) 450-6700 |
News Archive
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.
Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010.
BioRelix, Inc. today announced that it has entered into a research collaboration agreement with a subsidiary of Merck & Co., Inc. to identify new antibacterial drug candidates.
Marking another significant milestone for GE Healthcare's information technology business, the Ohio Pharmacy Board has approved the company's advanced ePrescribing solution for use by the state's physicians. Ohio is the only state today requiring two-factor authentication.
› Verified 2 days ago
Dr. Eric Brackett, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 711 Saint Marys Dr, Evansville, IN 47714 Phone: 812-485-5858 | |
Mason M Plater, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 415 W Columbia St Ste 110, Evansville, IN 47710 Phone: 181-245-0606 | |
John T Gallagher, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 Saint Marys Dr # 300, Evansville, IN 47714 Phone: 812-485-5300 | |
Dr. Scott M Cordts, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 W Columbia St, Ste 110, Evansville, IN 47710 Phone: 812-450-3363 Fax: 812-450-3071 | |
Dr. Janet Marie Kelley, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 Bellemeade Ave Ste 200b, Evansville, IN 47714 Phone: 812-485-3737 | |
Natasha Elizabeth Mathew, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 415 W Columbia St Ste 110, Evansville, IN 47710 Phone: 812-450-3363 Fax: 812-450-3071 | |
Mike Sebastian, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3801 Bellemeade Ave, Suite 200-b, Evansville, IN 47714 Phone: 812-485-3737 Fax: 812-485-1704 |